Scientific Advisory Board

Biosynex has set up a Scientific Advisory Board whose mission is to advise the scientific strategy of the company. It includes leading scientist and experts specializing in the scientific topics of Biosynex.

portait-3Felix Agbalika (MD)

Assistant-professor and teacher-researcher at D.Diderot Paris VII University after he graduated from Pasteur Institute – Paris in Virology, Bacteriology , Immunology and Molecular Biology.

He also graduated at Paris VII- University in master of Sciences ( MSc ) in Biochemistry and is qualified to research management (HDR). Before joining Paris VII University F.Agbalika served at Nancy University I as assistant in the field of environmental microbiology, particularly in virology.. Thus he contributed to the success of new guidelines for control of treated waste waters (French Standards AFNOR ).He has also obtained the post-graduate qualification (DEA) in Microbiology -Drugs .
At Paris VII University in Research Unity 3715 extended to 3963, Felix Agbalika continued his career in retroviroloy domain focusing on HIV and HTLV1/2 in transplant patients and several clinical trials. Recently his activity was focused on the new viruses associated with malignant diseases like Kaposi Sarcoma , Multicentric Castleman Disease , Primary Effusion Lymphoma .and Merkel Sarcoma . He is member of Committee of good guidelines in blood transfusion (St-Louis Hospital Paris ). He has also initiated works leading to patent FR 08 01604 which is commonly owned by Biosynex, Paris VII University and APHP (Assistance Publique Hôpitaux de Paris).
Dr Felix Agbalika is reviewer for AIDS, J. Acquired Immune Def Syndrome , Clinica Chimica Acta.

Emmanuel Drouet (PharmD)

Group leader in the UVHCI (Unit of Virus-Host Cell Interactions UMI 3265 CNRS – UJF- EMBL, Grenoble).

Since the early 80’s Emmanuel Drouet focused on generation of monoclonal antibodies for biomedical purpose. He received his PhD in Clinical Virology from the Université Claude-Bernard (Lyon) in 1991 and has been leading diagnosis and development activities at Institut Pasteur (Lyon) in the area of viral diseases (herpes viruses) since this date. Emmanuel Drouet has an excellent track record in herpes virus field, and his group is engaged in clinical research in the field of EBV diseases. Current research included the field of Hepatitis C Virus research, leading to elucidation of some aspects of its epidemiology and control. He is currently professor of Virology at Grenoble University (Faculty of Pharmacy). He’s member of the steering Committee of the master Erasmus Mundus “Biohealth Computing” recently selected by the EACEA (Education Audiovisual & Culture Executive Agency).

Denis Gallot (MD, PhD)

Head of the labour ward in the Clermont-Ferrand University Hospital (France).

He is Professor of Obstetrics and Gynaecology at the Medical School (Université d’Auvergne). He is a specialist of Foetal Medicine. He works in close collaboration with Dr. Vincent Sapin by directing one subgroup (lung development) of the team “Metabolic and molecular implications of retinoids during human development”, belonging to the “Génétique, Reproduction et Développement” (UMR CNRS 6247, Clermont Universités, INSERM U.931). He wrote more than 60 scientific papers mainly focused on lung development including congenital diaphragmatic hernia, management of complicated twin pregnancies, rupture of membranes and prenatal detection of foetal anomalies. He is a full member of the Collège National des Gynécologues Obstétriciens Français, the Société Française de Médecine Périnatale and the Club de Médecine Foetale. He is the national secretary for the Journées Francophones de Recherche en Obstétrique et Gynécologie since 2009. Dr Gallot’s clinical research includes fetoscopic therapy and rupture of membranes.

Vincent Sapin (PharmD, PhD)

Head of the “Biochemistry and Molecular Biology” Department of the Clermont-Ferrand University Hospital (France).

Dr. Sapin is Professor of Biochemistry and Molecular Biology at the Medical School (Université d’Auvergne). He’s the leader of a research group intituled “Metabolic and molecular implications of retinoids during human development”, belonging to the “Génétique, Reproduction et Développement” (UMR CNRS 6247, Clermont Universités, INSERM U.931). He wrote more than 50 scientific papers focused on the physiopathology of two tissues in links with the retinoids hypothesis: amniotic membranes (premature rupture of membranes) and lung (congenital diaphragmatic hernia). He is member of the American Association of Clinical Chemistry, the French Society of Biological Chemistry and is certified by the European Communities Confederation of Clinical Chemistry. Dr. Sapin’s clinical research includes, point of care biochemical (CRP, cardiac peptides) markers, biochemistry analyses of amniotic fluid (proteins, volatile organic compounds) in normal and pathological (twin-twin syndrome, premature rupture of membrane) and recently initiated a French scientific group on the biomarkers of the fetal alcohol syndrome.